📣 VC round data is live. Check it out!
- Public Comps
- Precision BioSciences
Precision BioSciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Precision BioSciences and similar public comparables like Pyridam Farma, PhotoCure, Atrium Therapeutics, Camp4 Therapeutics and more.
Precision BioSciences Overview
About Precision BioSciences
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Founded
2006
HQ

Employees
108
Website
Financials (LTM)
EV
$110M
Valuation Multiples
Start free trialPrecision BioSciences Financials
Precision BioSciences reported last 12-month revenue of $27M and negative EBITDA of ($54M).
In the same LTM period, Precision BioSciences generated $27M in gross profit, ($54M) in EBITDA losses, and had net loss of ($54M).
Revenue (LTM)
Precision BioSciences P&L
In the most recent fiscal year, Precision BioSciences reported revenue of $34M and EBITDA of ($42M).
Precision BioSciences is unprofitable as of last fiscal year, with EBITDA margin of (124%) and net margin of (133%).
Financial data powered by Morningstar, Inc.
Precision BioSciences Stock Performance
Precision BioSciences has current market cap of $197M, and enterprise value of $110M.
Market Cap Evolution
Precision BioSciences' stock price is $7.64.
Precision BioSciences share price increased by 6.9% in the last 30 days, and by 58.3% in the last year.
Precision BioSciences has an EPS (earnings per share) of $-1.77.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $110M | $197M | 5.0% | 6.9% | 82.0% | 58.3% | $-1.77 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPrecision BioSciences Valuation Multiples
Precision BioSciences trades at 4.1x EV/Revenue multiple, and (2.1x) EV/EBITDA.
EV / Revenue (LTM)
Precision BioSciences Financial Valuation Multiples
As of May 5, 2026, Precision BioSciences has market cap of $197M and EV of $110M.
Precision BioSciences has a P/E ratio of (3.7x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Precision BioSciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Precision BioSciences Margins & Growth Rates
In the most recent fiscal year, Precision BioSciences reported EBITDA margin of (124%) and net margin of (133%).
Precision BioSciences Margins
Precision BioSciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Precision BioSciences Operational KPIs
Precision BioSciences' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.8M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Precision BioSciences Competitors
Precision BioSciences competitors include Pyridam Farma, PhotoCure, Atrium Therapeutics, Camp4 Therapeutics, Medeze Group, Elicio Therapeutics, Macrogenics, Cartesian Therapeutics, OmniAb and Humacyte.
Most Precision BioSciences public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.9x | — | (69.9x) | — | |||
| 3.0x | 2.8x | 42.2x | 20.6x | |||
| (3.6x) | (5.5x) | 0.9x | — | |||
| 26.6x | 24.8x | (1.8x) | (1.3x) | |||
| 6.6x | — | 17.1x | — | |||
| — | — | (5.3x) | — | |||
| 0.3x | 0.4x | (0.8x) | — | |||
| 34.6x | 49.2x | (1.2x) | — | |||
This data is available for Pro users. Sign up to see all Precision BioSciences competitors and their valuation data. Start Free Trial | ||||||
Precision BioSciences Funding History
Before going public, Precision BioSciences raised $136M in total equity funding, across 2 rounds.
Precision BioSciences Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Precision BioSciences
| When was Precision BioSciences founded? | Precision BioSciences was founded in 2006. |
| Where is Precision BioSciences headquartered? | Precision BioSciences is headquartered in United States. |
| How many employees does Precision BioSciences have? | As of today, Precision BioSciences has over 108 employees. |
| Who is the CEO of Precision BioSciences? | Precision BioSciences' CEO is Michael Amoroso. |
| Is Precision BioSciences publicly listed? | Yes, Precision BioSciences is a public company listed on Nasdaq. |
| What is the stock symbol of Precision BioSciences? | Precision BioSciences trades under DTIL ticker. |
| When did Precision BioSciences go public? | Precision BioSciences went public in 2019. |
| Who are competitors of Precision BioSciences? | Precision BioSciences main competitors include Pyridam Farma, PhotoCure, Atrium Therapeutics, Camp4 Therapeutics, Medeze Group, Elicio Therapeutics, Macrogenics, Cartesian Therapeutics, OmniAb, Humacyte. |
| What is the current market cap of Precision BioSciences? | Precision BioSciences' current market cap is $197M. |
| What is the current revenue of Precision BioSciences? | Precision BioSciences' last 12 months revenue is $27M. |
| What is the current revenue growth of Precision BioSciences? | Precision BioSciences revenue growth (NTM/LTM) is (52%). |
| What is the current EV/Revenue multiple of Precision BioSciences? | Current revenue multiple of Precision BioSciences is 4.1x. |
| Is Precision BioSciences profitable? | No, Precision BioSciences is not profitable. |
| What is the current EBITDA of Precision BioSciences? | Precision BioSciences has negative EBITDA and is not profitable. |
| What is Precision BioSciences' EBITDA margin? | Precision BioSciences' last 12 months EBITDA margin is (199%). |
| What is the current EV/EBITDA multiple of Precision BioSciences? | Current EBITDA multiple of Precision BioSciences is (2.1x). |
| What is the current FCF of Precision BioSciences? | Precision BioSciences' last 12 months FCF is ($49M). |
| What is Precision BioSciences' FCF margin? | Precision BioSciences' last 12 months FCF margin is (180%). |
| What is the current EV/FCF multiple of Precision BioSciences? | Current FCF multiple of Precision BioSciences is (2.3x). |
| How many companies Precision BioSciences has acquired to date? | Precision BioSciences hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Precision BioSciences has invested to date? | Precision BioSciences hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Precision BioSciences
Lists including Precision BioSciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.